Immune Checkpoint Inhibitor-Associated Pericarditis.
Immune-related adverse events
NSCLC
Pericarditis
Journal
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
ISSN: 1556-1380
Titre abrégé: J Thorac Oncol
Pays: United States
ID NLM: 101274235
Informations de publication
Date de publication:
06 2019
06 2019
Historique:
received:
27
11
2018
revised:
20
02
2019
accepted:
28
02
2019
pubmed:
10
3
2019
medline:
22
7
2020
entrez:
10
3
2019
Statut:
ppublish
Résumé
Side effects of immune checkpoint inhibitors, termed immune-related adverse events, are relatively common, but immune checkpoint inhibitor-mediated cardiotoxicities are rare; however, they can be serious and potentially fatal. Pericarditis is an infrequent cardiac toxicity of immunotherapy and predisposing factors remain unknown. Here we report three patients with NSCLC who developed pericarditis during therapy with programmed death 1/programmed death ligand 1+/- CTLA-4 inhibitors. We review the clinical presentation of these three cases and histopathologic findings from autopsies from the first two patients and a pericardial sampling that has been obtained from a pericardial window procedure in the third patient who recovered from the pericarditis episode. We also discuss the potential mechanisms, as well as what is known about pericarditis secondary to immune-related adverse events.
Identifiants
pubmed: 30851443
pii: S1556-0864(19)30196-0
doi: 10.1016/j.jtho.2019.02.026
pmc: PMC6617516
mid: NIHMS1527209
pii:
doi:
Substances chimiques
Antineoplastic Agents, Immunological
0
Types de publication
Case Reports
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1102-1108Subventions
Organisme : NCI NIH HHS
ID : P30 CA016359
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA196530
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States
Informations de copyright
Copyright © 2019 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.
Références
J Am Coll Cardiol. 2018 Apr 24;71(16):1755-1764
pubmed: 29567210
PLoS One. 2015 Apr 22;10(4):e0124059
pubmed: 25902191
N Engl J Med. 2016 Nov 03;375(18):1749-1755
pubmed: 27806233
JAMA Oncol. 2018 Dec 1;4(12):1721-1728
pubmed: 30242316
N Engl J Med. 2014 Dec 18;371(25):2410-6
pubmed: 25517707
J Thorac Oncol. 2018 Apr;13(4):510-520
pubmed: 29247829
JAMA Oncol. 2019 Mar 1;5(3):376-383
pubmed: 30589930
Circulation. 2017 Nov 21;136(21):2085-2087
pubmed: 29158217
BMJ Case Rep. 2016 Jul 20;2016:
pubmed: 27440853
J Immunol. 2008 Aug 15;181(4):2513-21
pubmed: 18684942
Circ Res. 2007 Aug 3;101(3):248-57
pubmed: 17569889
Ann Oncol. 2016 Jul;27(7):1362
pubmed: 27072927
Case Rep Oncol Med. 2015;2015:794842
pubmed: 25918658
J Immunother Cancer. 2015 Apr 21;3:11
pubmed: 25901283
Oncologist. 2018 Aug;23(8):874-878
pubmed: 29802220